Drugs / HSV1716
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02031965 | Dec 2013 → May 2016 | anaplastic astrocytoma, anaplastic oligodendroglioma, giant cell glioblastoma, gliomatosis cerebri +1 | Pediatric Brain Tumor Consortium | Terminated | No outcome recorded |
| Phase 1 | NCT00931931 | Mar 2010 → Mar 2018 | Ewing sarcoma, Wilms tumor, clivus chordoma, malignant peripheral nerve sheath tumor +3 | Timothy Cripe | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01721018 | Oct 2012 → Nov 2016 | malignant pleural mesothelioma | Virttu Biologics Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSV1716 | “This phase I trial studies the side effects and the safety of injecting HSV1716 (a new experimental therapy) into or near the tumor resection cavity.” NCT02031965 ↗ |
| Modality | Other / unclassified | “HSV1716, an oncolytic virus” NCT00931931 ↗ |
| Route | Other | “receiving HSV1716 as an intratumoral injection” NCT00931931 ↗ |